Business Context and Reporting Period
Company: Imprimis Pharmaceuticals, Inc. (Note: Metadata referenced "Harrow, Inc." but the filing text identifies Imprimis Pharmaceuticals, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: November 26, 2014 (Signed December 2, 2014)
Event: Entry into a Material Definitive Agreement to acquire South Coast Specialty Compounding, Inc. D/B/A Park Compounding ("Park").
Key Financial Metrics and Transaction Terms
This filing details a specific acquisition agreement rather than periodic financial performance. Key financial terms of the transaction include:
- Total Consideration Structure: Cash and restricted common stock.
- Upfront Cash Payment: $3,000,000 (subject to working capital adjustments).
- Upfront Stock Payment: Restricted common stock valued at $500,000 (based on 10-day average closing price).
- Deferred Payments: 12 quarterly cash payments of $53,125 each over three years, totaling $637,500.
- Stock Option on Deferred Payments: Sellers may elect to receive the final six payments (up to $318,750) in restricted common stock instead of cash.
- Expected Closing Date: On or about January 1, 2015.
Note: The filing does not provide the Company's current revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes and Outlook
Material Change: The Company has entered into a definitive agreement to acquire Park, a compounding pharmacy accredited by the Pharmacy Compounding Accreditation Board located in Irvine, California. This represents a strategic expansion into compounding services.
Outlook and Conditions:
- The transaction is subject to customary closing conditions, including the entry into employment arrangements with the Sellers.
- The agreement may be terminated if the acquisition does not close by February 28, 2015.
- Forward-looking statements indicate potential risks regarding transaction delays, integration difficulties, and regulatory developments impacting compounding pharmacies.
Investor Verification Checklist
- Verify the final closing date and whether the transaction closed by the February 28, 2015 deadline.
- Confirm the final working capital adjustment amount affecting the $3,000,000 cash purchase price.
- Monitor the stock price at closing to determine the exact number of shares issued for the $500,000 upfront and potential deferred stock components.
- Review subsequent filings for details on the integration of Park Compounding and any regulatory approvals required.
- Check for any termination of the agreement prior to closing.